|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM359495249 |
| 003 |
DE-627 |
| 005 |
20240923001147.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/VIW.20200110
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1544.xml
|
| 035 |
|
|
|a (DE-627)NLM359495249
|
| 035 |
|
|
|a (NLM)37448778
|
| 035 |
|
|
|a (PII)20200110
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Monaco, Hailey
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 22.09.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a Among modalities of cancer immunotherapy, near-infrared photoimmunotherapy (NIR-PIT) has reached significant preclinical and clinical stages and quickly evolved over the last 5 years. NIR-PIT uses deep-penetrable NIR light to induce physicochemical changes in the antibody-photosensitizer conjugate (APC), leading to resultant necrosis and immunogenic cell death (ICD) of the cancer cells. Alternatively, other types of photomedicine use photosensitizers to convert absorbed light energy either into reactive oxygen species for photodynamic therapy (PDT) or into heat for photothermal therapy (PTT). ICD is a unique and relevant outcome of NIR-PIT because it induces long-lasting antitumor host immunity, which overcomes the immunosuppressive network of cancer. Due to its high specificity and durable antitumor effects, NIR-PIT is now considered a promising cancer therapy, and optimized NIR-PIT is readily expanding its applicability to many different types of cancer. Along with the traditional method of NIR-PIT, new avenues in its realm of treatment are currently being explored, such as the targeting of other immunosuppressive elements, delivery of NIR light through a catheter, real-time imaging for tumor detection, and the use of tumor-seeking small molecules for improved efficacy and safety. In addition, its effect on hyperpermeability has opened a door for a wide array of combination therapies with other modalities. This review summarizes the recent findings in clinical and preclinical studies of NIR-induced photomedicine and its future significance in the field of cancer research
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a immunogenic cell death
|
| 650 |
|
4 |
|a near-infrared photoimmunotherapy
|
| 650 |
|
4 |
|a photodynamic therapy
|
| 650 |
|
4 |
|a photothermal therapy
|
| 700 |
1 |
|
|a Yokomizo, Shinya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Choi, Hak Soo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kashiwagi, Satoshi
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t View (Beijing, China)
|d 2020
|g 3(2022), 3 vom: 30. Mai
|w (DE-627)NLM333040546
|x 2688-268X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:3
|g year:2022
|g number:3
|g day:30
|g month:05
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/VIW.20200110
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_21
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_62
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_100
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_138
|
| 912 |
|
|
|a GBV_ILN_147
|
| 912 |
|
|
|a GBV_ILN_176
|
| 912 |
|
|
|a GBV_ILN_179
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_813
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2002
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2004
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2007
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2009
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2011
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2014
|
| 912 |
|
|
|a GBV_ILN_2015
|
| 912 |
|
|
|a GBV_ILN_2016
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 912 |
|
|
|a GBV_ILN_2020
|
| 912 |
|
|
|a GBV_ILN_2031
|
| 912 |
|
|
|a GBV_ILN_2039
|
| 912 |
|
|
|a GBV_ILN_2285
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 2022
|e 3
|b 30
|c 05
|